Trinity Biotech Has Received Regulatory Approval To Conduct Initial European Pre-Pivotal Trial, The Data Will Be Utilized To Advance The Technical Optimization Of The Next Generation CGM Device Ahead Of The Pivotal Trial Planned In 2025
Trinity Biotech Has Received Regulatory Approval To Conduct Initial European Pre-Pivotal Trial, The Data Will Be Utilized To Advance The Technical Optimization Of The Next Generation CGM Device Ahead Of The Pivotal Trial Planned In 2025
trinity biotech已獲得監管批准，進行首次歐洲前支點試驗，數據將用於在2025年計劃進行的支點試驗前推進下一代CGM設備的技術優化。
Trinity Biotech Has Received Regulatory Approval To Conduct Initial European Pre-Pivotal Trial, The Data Will Be Utilized To Advance The Technical Optimization Of The Next Generation CGM Device Ahead Of The Pivotal Trial Planned In 2025
trinity biotech已獲得監管批准，進行首次歐洲前支點試驗，數據將用於在2025年計劃進行的支點試驗前推進下一代CGM設備的技術優化。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。